Top San Francisco Bay Area, CA Biotech Companies (201)
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the development of breakthrough products. Help us bring modern software to modern science. We’re on Team Science We believe in the promise of science and the teamwork required to fulfill that promise. Whether your background is in science, engineering, business, or another field, you’re on Team Science if you believe in the power of science to solve the world’s most pressing problems.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Endpoint is an interactive response technology (IRT®) systems and solutions provider that supports the life sciences industry. Since 2009, we have been working with a single vision in mind, to help sponsors and pharmaceutical companies achieve clinical trial success. Our solutions, realized through the proprietary PULSE® platform, have proven to maximize the supply chain, minimize operational costs, and ensure timely and accurate patient dosing. Endpoint is headquartered in Wakefield, Massachusetts with offices across the United States, Europe, and Asia. Endpoint is a subsidiary of Fortrea Holdings, Inc.
DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. At Pliant, we share a commitment and a clear passion to drive innovative science towards addressing areas of unmet medical need. Together we believe we have the power to make a difference in the lives of patients and those impacted by fibrotic diseases. We believe that by harnessing the therapeutic potential of integrin biology and TGF-β modulation, there is a potential to create drug candidates aimed at halting or even reversing fibrotic diseases. Pliant recognizes the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. Pliant is an equal opportunity employer and does not discriminate against any individual or potential candidate based on race, color, religion, sex, national origin, sexual preference or any other legally protected category. Pliant is located in South San Francisco, California, the birthplace of biotechnology. Proud to be a San Francisco Business Times Best Place to Work in 2023. Learn more about how we are breaking ground in the treatment of fibrotic diseases at www.PliantRx.com.
Helix is a rapidly growing startup focused on personal genomics. Helix has a simple but powerful mission: to empower every person to improve their life through DNA. We’re creating an ecosystem where people can explore diverse and uniquely personalized applications provided by high-quality partners.
Trusted by the world's leading organizations, Point B is a consulting firm that works at the intersection of expertise, industry insight, and transformative technology. This collaborative approach enables you to solve your most important challenges, by bringing together the right mix of talent and technology to deliver greater value and impact. With over 850 associates in the US and 3000+ consultants around the world through our Nextcontinent partnership, we work where you do to deliver the change you seek.
Avive dares to imagine a world where a culture of response becomes the norm, and no witnessed Sudden Cardiac Arrest (SCA) goes untreated. We are a Bay Area MedTech company developing lifesaving solutions designed to empower everyday people to do extraordinary things. Our new Automated External Defibrillators (AEDs) and response system are designed to offer advanced and user-friendly features in a compact, intuitive, more affordable, and connected device. Avive seeks to save lives by making owning, using and managing AEDs simple. Despite tackling a massive and complex public health issue, which has had the same dismal survival rate of 10% for decades, Avive does so with optimism and fervor. Fueled by the words and experiences of those whose lives have been impacted or lost to SCA, the Avive team has simply refused to accept the status quo, working relentlessly to move the needle on survival rates. Rory Beyer, Moseley Andrews, and Sameer Jafri came together with a seemingly simple idea – that anyone can and should be able to positively impact the outcome of a Sudden Cardiac Arrest (SCA) rescue. Drawn together by their complementary skills and background, they met at a conference focused on SCA prevention and quickly came to share a vision for the profound impact that a more effective solution could have on thousands of families every year. With Rory and Moseley’s technical expertise and a novel AED concept they had developed at MIT, combined with Sameer’s experience in SCA prevention through his non-profit organization – Saving Hearts Foundation, the three co-founded Avive in 2017. Our story is just beginning, and we hope you’ll come write it with us. https://youtu.be/XUiwcB_9bzw We are actively hiring, see how you can contribute at https://avive.life/careers/
Vir Biotechnology, Inc. (in Europe, Humabs BioMed, https://bit.ly/46lQGN2) is an immunology company focused on powering the immune system to address unmet patient needs in infectious disease and beyond. Our powerful R&D engine combines our proprietary monoclonal antibody (mAb) platform with machine learning and artificial intelligence-enhanced capabilities, enabling us to engineer our rich database of human antibodies and deliver transformative medicines for diseases with significant global burden. Our current pipeline consists of multiple clinical candidates targeting hepatitis B and hepatitis delta viruses and human immunodeficiency virus, including a potential functional cure for chronic hepatitis B and treatment for chronic hepatitis delta. Our portfolio of broad, potent investigational monoclonal antibodies also targets influenza A and B viruses, COVID-19, respiratory syncytial virus/human metapneumovirus and human papillomavirus, and our investigational T cell vaccine aims to prevent HIV. Explore our full pipeline: https://bit.ly/3tr7FPm We collaborate with some of the world’s leaders in industry as well as government agencies and non-profit organizations enabling us to rapidly advance cutting-edge scientific discoveries and innovative technologies with the potential to benefit people around the world. We are proud to have been ranked the fastest-growing company in North America on the 2022 Deloitte Technology Fast 500™. Join us as we pursue our mission to transform lives. It has come to our attention that there have been various recruitment scams targeting job seekers on LinkedIn. Vir Biotechnology, Inc. is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir’s recruiting process: https://bit.ly/461EgJN
ABOUT BRIGHTSEED Brightseed is a world leader in biosciences and artificial intelligence that illuminates nature to restore human health. Through our Forager® A.I., Brightseed helps companies gain the deepest insight into bioactives and their innovation potential. Forager accelerates bioactive discovery and biological validation from years to months – and is rapidly revealing new connections between nature and humanity. Brightseed partners with companies across the consumer health continuum to provide novel insights and science-backed health solutions. ABOUT BIOACTIVES Bioactives are small molecule compounds produced by plants, fungi, and microbes that grow in and adapt to environments that present a wide range of challenges to their survival. Bioactives also benefit the health of humans – they are the enlivening caffeine in tea, the powerful antioxidant lycopene in tomatoes, and they inform active ingredients in medicines like Taxol, Aspirin and Metformin, a first-line treatment for Type 2 diabetes, derived from the French lilac flower. Science has long known that bioactives are critical to human health, yet the vast majority remain unknown and uncharted. Brightseed’s A.I., Forager®, discovers bioactives in nature and maps them to human health outcomes at a rate and accuracy that was previously impossible.
Pendulum is committed to developing novel interventions that target the human microbiome to improve the lives of patients suffering from a variety of diseases. Our targeted formulations of natural bacterial strains help to rebalance the microbiome which restores and improve one’s health.
Twist Bioscience is a synthetic biology company based in South San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA. Twist Bioscience serves Life Science researchers who are changing the world for the better. Coming from diverse fields of medicine, agriculture, industrial chemicals and data storage, scientists use our synthetic genes, oligo pools, and NGS target enrichment to better lives and improve the sustainability of the planet. Twist Bioscience is uniquely positioned to help accelerate these efforts by providing precision at a scale that is otherwise unavailable. Our technology overcomes inefficiencies and enables cost-effective, rapid, precise, high-throughput DNA synthesis and sequencing. We offer both the quality and quantity researchers need now to rapidly realize opportunities ahead.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours.
Gladstone's mission is to drive a new era of discovery in disease-oriented science and to mentor tomorrow’s leaders in an inspiring and diverse environment. Although Gladstone shares traits with other top life science organizations, we pride ourselves on taking uncommon scientific paths to overcoming disease. Our investigators are selected to become authorities in leading or creating new fields, and we work to provide them with resources to explore bold new thoughts, form effective scientific teams, and create or master emerging research technologies that accelerate progress—Gladstone’s special recipe for success that has yielded some of the most important biomedical advances of our time. Our three disease-focused institutes constitute the core of our discovery engine, but do not operate in isolation. We are seizing unprecedented opportunities for “convergence”—defined as the blending of intellectual and physical assets from multiple scientific disciplines and fields to speed the discovery process in our attack on unsolved health problems that affect almost every human family.
Insitro is a data-driven drug discovery and development company.
The Chan Zuckerberg Biohub Network is a group of nonprofit research institutes that bring together physicians, scientists, and engineers with the goal of pursuing grand scientific challenges on 10- to 15-year time horizons. These institutes partner with Chan Zuckerberg Science in its goal to understand the mysteries of the cell and how cells interact within systems. This collaboration will bring us closer to our mission to cure, prevent, or manage all disease by the end of the century. CZ Biohub San Francisco — which was the inaugural Biohub and launched in 2016 — focuses on infectious disease, quantitative cell science, and technology platforms. It also has an investigator program supporting early-stage, risky research of scientists at Stanford University, UC Berkeley, and UCSF. CZ Biohub Chicago, which launched in 2023, focuses on engineering technologies to make precise, molecular-level measurements of biological processes within human tissues, with an ultimate goal of understanding and treating the inflammatory states that underlie many diseases. It is a collaboration between the University of Chicago, Northwestern University, and the University of Illinois Urbana-Champaign.
GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible. The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease. We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.
Epicrispr Biotechnologies is a biotechnology company developing ultracompact therapies to modulate gene expression in vivo using the smallest known Cas protein, CasMINI
Pivot Bio is a sustainable agriculture company delivering farmers patented crop nutrition technologies that harness the power of nature to reliably and productively grow the food the world needs in the face of increasing volatility.
Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.
Work Your Passion. Live Your Purpose.
